Recurrent Adult Immunoblastic Large Cell Lymphoma Completed Phase 1 Trials for DB00188 (Bortezomib)

IndicationStatusPhase
DBCOND0028500 (Recurrent Adult Immunoblastic Large Cell Lymphoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00054483Bortezomib in Treating Patients With Advanced Cancer and Kidney DysfunctionBasic Science
NCT00348985PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasTreatment